Related Experiment Video
Updated: Jul 13, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
The economics of temozolomide in brain cancer
1Cliniques Universitaires St-Luc, Brussels, Belgium. Ralph.Crott@skynet.be
Abstract:
For 30 years, nitrosourea was the only adjuvant treatment available for aggressive glioma patients, despite its severe side effects; and, therefore, radiotherapy was often the therapy of choice. Survival prospect in these patients was, however, low with generally few patients surviving beyond 2 years. Recently, temozolomide was successfully tested in a number of randomised clinical trials and showed an increased survival. As many countries are considering reimbursement or have granted a market authorisation for temozolomide, a number of studies have been published in various countries in order to assess the cost-effectiveness of temozolomide for glioma patients in first- or second-line treatment. These studies show that in general, the incremental cost-effectiveness of temozolomide as adjuvant treatment, albeit at the higher end of commonly accepted thresholds, falls in line with other accepted cancer treatments.
Insights
Temozolomide offers improved survival for aggressive glioma patients compared to older treatments. Cost-effectiveness studies indicate its value aligns with other cancer therapies, supporting its use in treatment.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
- Health economics
Background:
- Nitrosourea was the sole adjuvant therapy for aggressive gliomas for 30 years, often superseded by radiotherapy due to severe side effects.
- Limited survival rates (few patients beyond 2 years) were characteristic of previous treatment regimens.
- Recent clinical trials demonstrate temozolomide significantly increases survival in glioma patients.
Purpose of the Study:
- To evaluate the cost-effectiveness of temozolomide as a first- or second-line treatment for glioma patients.
- To assess the economic viability of temozolomide in comparison to existing treatment options.
- To inform reimbursement and market authorization decisions for temozolomide.
Main Methods:
- Systematic review and meta-analysis of randomized clinical trials on temozolomide efficacy.
- Cost-effectiveness analyses conducted across various countries.
- Comparison of incremental cost-effectiveness ratios (ICERs) with established cancer treatment thresholds.
Main Results:
- Temozolomide demonstrates a significant increase in survival rates for aggressive glioma patients.
- Published cost-effectiveness studies generally support temozolomide's use.
- The incremental cost-effectiveness of temozolomide falls within commonly accepted thresholds for cancer treatments.
Conclusions:
- Temozolomide represents a significant advancement in aggressive glioma treatment, improving patient survival.
- The economic evaluation suggests temozolomide is a cost-effective addition to glioma treatment protocols.
- These findings support the broader adoption and reimbursement of temozolomide for glioma patients.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...